Q-omics provides the consensus-scored PRAMEF14 profile across patient tissues and cancer cell-line models. PRAMEF14 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Additionally, PRAMEF14 RNA expression shows 7,944 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where PRAMEF14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF14 survival associations across molecular data types. PRAMEF14 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF14 RNA expression–survival associations across cancer types. High PRAMEF14 expression shows unfavorable associations in KIRC, SCLC, CESC, BLCA, THCA and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for PRAMEF14 RNA expression.
This table shows molecular features associated with PRAMEF14 in patient tissues and cancer cell lines. In patient samples, PRAMEF14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
